Denali CEO’s Insider Sale Is Just Routine Tax Planning, Not a Shift in Strategy
Denali Therapeutics’ CEO’s recent share sale is a routine tax‑planning move that leaves the company’s 11 % stake intact, highlighting ongoing confidence in its lysosomal‑storage disease pipeline and strong market position.
3 minutes to read